Sugi Predict

Sugi Predict / Compounds / SCHEMBL248563

SCHEMBL248563

SCHEMBL248563

Fc1ccc([C@H]2CO2)cc1F

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 1/20 0.47
▸ HTR2C P28335 1/20 0.47
▸ HTR2B P41595 1/20 0.47
▸ TSHR P16473 1/20 0.44
▸ PARP1 P09874 1/20 0.39
▸ GSTO1 P78417 3/20 0.38
▸ IDO1 P14902 2/20 0.38
▸ TDO2 P48775 2/20 0.38
▸ KDM1A O60341 2/20 0.37
▸ MAOB P27338 1/20 0.37
▸ BACE1 P56817 1/20 0.36
▸ SLC6A2 P23975 1/20 0.36
▸ SLC6A4 P31645 1/20 0.36
▸ SLC6A3 Q01959 1/20 0.36
▸ DRD3 P35462 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL808678 1.00 HTR2A (0.47) HTR2AHTR2CHTR2BTSHRPARP1
SCHEMBL15196460 1.00 HTR2A (0.47) HTR2AHTR2CHTR2BTSHRPARP1
SCHEMBL29634686 1.00 HTR2A (0.47) HTR2AHTR2CHTR2BTSHRPARP1
SCHEMBL29478276 1.00 HTR2A (0.47) HTR2AHTR2CHTR2BTSHRPARP1
Toluene SCHEMBL28202213 0.86 TSHR (0.47) HTR2AHTR2CHTR2BTSHRPARP1
SCHEMBL25262338 0.81 TSHR (0.40) HTR2AHTR2CHTR2BTSHRPARP1
SCHEMBL29628352 0.81 SLC6A2 (0.45) TSHRPARP1GSTO1IDO1TDO2
SCHEMBL31068687 0.81 ABCC9 (0.45) TSHR
SCHEMBL25303721 0.81 ABCC9 (0.45) TSHR
SCHEMBL16462593 0.81 GSTO1 (0.49) TSHRPARP1GSTO1SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119662577-A A preparation method Ticagrelor intermediate styrene monooxygenase mutants of the body 中国科学院成都生物研究所 2025-03-21 — — CN claimed
CN-111073919-B Method for preparing (S) -2- (3, 4-difluorophenyl) oxirane 尚科生物医药（上海）有限公司 2024-06-07 — — CN claimed
CN-115710158-A Method for preparing ticagrelor intermediate through asymmetric catalysis 凯特立斯（深圳）科技有限公司 2023-02-24 — — CN claimed
CN-109956916-A A kind of method preparing (S) -2- (3,4- difluorophenyl) ethylene oxide 乐山职业技术学院 2019-07-02 — — CN claimed
US-20120136167-A1 Processes For The Preparation Of Optically Active Intermediates ASTRAZENECA AB (SE) 2012-05-31 — — US claimed
CN-120210142-A StyA mutant and encoding gene, preparation method and application thereof 核芯生物医药科技(杭州)有限公司 2025-06-27 — — CN disclosed
CN-119662577-A A preparation method Ticagrelor intermediate styrene monooxygenase mutants of the body 中国科学院成都生物研究所 2025-03-21 — — CN disclosed
CN-119662577-A A preparation method Ticagrelor intermediate styrene monooxygenase mutants of the body 中国科学院成都生物研究所 2025-03-21 — — CN disclosed
CN-111073919-B Method for preparing (S) -2- (3, 4-difluorophenyl) oxirane 尚科生物医药（上海）有限公司 2024-06-07 — — CN disclosed
CN-111073919-B Method for preparing (S) -2- (3, 4-difluorophenyl) oxirane 尚科生物医药（上海）有限公司 2024-06-07 — — CN disclosed
CN-111073919-B Method for preparing (S) -2- (3, 4-difluorophenyl) oxirane 尚科生物医药（上海）有限公司 2024-06-07 — — CN disclosed
WO-2023223335-A1 A METHOD FOR PREPARING (1S)-2-CHLORO-1-(3,4-DIFLUOROPHENYL) ETHANOL AARTI PHARMALABS LIMITED (IN) 2023-11-23 — — WO disclosed
WO-2011132083-A2 NOVEL PROCESS FOR PREPARING PHENYLCYCLOPROPYLAMINE DERIVATIVES USING NOVEL INTERMEDIATES ACTAVIS GROUP PTC EHF (IS) 2011-10-27 — — WO disclosed
US-8026396-B2 Processes for the preparation of optically active intermediates ASTRAZENECA AB (SE) 2011-09-27 — — US disclosed
US-20100331575-A1 Processes For The Preparation Of Optically Active Intermediates ASTRAZENECA AB (SE) 2010-12-30 — — US disclosed
US-7790927-B2 Using hypochlorite in water in presence of alkali metal hydroxide ASTRAZENECA AB (SE) 2010-09-07 — — US disclosed
EP-2049463-A1 A PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE CYCLOPROPYLAMINES Astra Zeneca AB (SE) 2009-04-22 — — EP disclosed
WO-2008127275-A2 PYRROLINONE COMPOUNDS AS INHIBITORS OF BACTERIAL PEPTIDYL TRNA HYDROLASE AND USES THEREOF PTC THERAPEUTICS, INC. (US) 2008-10-23 — — WO disclosed
US-20080071114-A1 Processes For The Preparation Of Optically Active Intermediates ASTRAZENECA AB (SE) 2008-03-20 — — US disclosed
WO-2008018823-A1 A PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE CYCLOPROPYLAMINES ASTRAZENECA AB (SE) 2008-02-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080071114-A1 Processes For The Preparation Of Optically Active Intermediates DHPS, CYP1B1, CYP2S1 HTR2A 302/4885HTR2C 118/4885HTR2B 321/4885
US-20100331575-A1 Processes For The Preparation Of Optically Active Intermediates DHPS, CYP1B1, CYP2S1 HTR2A 302/4885HTR2C 118/4885HTR2B 321/4885
US-20120136167-A1 Processes For The Preparation Of Optically Active Intermediates DHPS, CYP2S1, CYP1B1 HTR2A 315/4885HTR2C 112/4885HTR2B 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.